SCHEMBL6818477

SCHEMBL6818477

COc1ccn2nc(-c3ccccc3)c(-c3ccc(=O)n(C4CCCN(C)C4)n3)c2c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA1 P30542 1/20 0.38
ITK Q08881 1/20 0.34
HTR1A P08908 1/20 0.34
HTR6 P50406 1/20 0.34
FGFR1 P11362 1/20 0.34
FGFR2 P21802 1/20 0.34
FGFR3 P22607 1/20 0.34
BTK Q06187 3/20 0.33
MAPK1 P28482 1/20 0.33
HDAC1 Q13547 1/20 0.33
HDAC8 Q9BY41 1/20 0.33
HDAC6 Q9UBN7 1/20 0.33
GSK3B P49841 1/20 0.33
KDM4E B2RXH2 1/20 0.33
MEN1 O00255 1/20 0.33
ALDH1A1 P00352 1/20 0.33
GLA P06280 1/20 0.33
GAA P10253 1/20 0.33
MAPT P10636 1/20 0.33
KMT2A Q03164 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6822534 0.90 FGFR1 (0.40) ADORA1FGFR1FGFR2FGFR3BTK
SCHEMBL7494888 0.87 ADORA1 (0.50) ADORA1MAPK1HDAC1HDAC8HDAC6
SCHEMBL6818744 0.84 BACE1 (0.39) ADORA1BACE1
SCHEMBL6824299 0.83 PDE1A (0.38) ADORA1MAPK1BACE1
SCHEMBL6818413 0.83 PDE1A (0.38) ADORA1MAPK1BACE1
SCHEMBL6818764 0.83 PDE1A (0.38) ADORA1MAPK1BACE1
SCHEMBL6822006 0.80 ADORA1 (0.46) ADORA1MAPK1
SCHEMBL6822151 0.76 ADORA1 (0.54) ADORA1
SCHEMBL6821959 0.75 ADORA1 (0.42) ADORA1FGFR1FGFR2FGFR3MAPK1
SCHEMBL6821431 0.75 ADORA1 (0.51) ADORA1MAPK1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040110763-A1 Pyrazolopyridine compound and pharmaceutical use thereof FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-06-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110763-A1 Pyrazolopyridine compound and pharmaceutical use thereof ADRB1, ADRA1D, ADRB3 ADORA1 22/4885ITK 2912/4885HTR1A 57/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.